A recent study reported the properties of new cinnamic acid-based derivatives as multifunctional cholinesterase inhibitors for Alzheimer’s disease, focused on the combination with benzyl-pyridinium salts used as scaffold to develop new AChE (acetylcholinesterase) and BuChE (butyrylcholinesterase) inhibitors [17]. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.